Brugada Ablation of VF Substrate Ongoing MultiCenter Registry

N/ACompletedNCT04420078

Pacific Rim Electrophysiology Research Institute159 enrolled

Overview

Current treatment of high-risk Brugada Syndrome (BrS) patients (pts) with recurrent VF is limited. Catheter ablation (CA) has been performed for BrS but a large study with long-term outcomes of CA in BrS ablation are lacking.

Brugada syndrome (BrS) patients who undergo BRS substrate ablations from tertiary centers for catheter ablations of complex arrhythmias from three continents - Asia, Europe and North America - are registered in a common database. The investigators exclude patients who were lost to follow up in the outpatient clinic.

Study Type

OBSERVATIONAL

Enrollment

159

Conditions

Brugada Syndrome

Interventions

Catheter AblationPROCEDURE

Ventricular fibrillation substrate

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Symptomatic Brugada Syndrome patients who had undergone catheter ablation of the arrhythmogenic substrates. Exclusion Criteria: * Patients who will not commit to regular follow up.

Locations (1)

Pacific Rim Electrophysiology Research Institute, Chulalongkorn University

Bangkok, Thailand

Outcomes

Primary Outcomes

Death

Expiration, unrelated to procedure

Time frame: 3 years

ICD Therapy for VT/VF

Electrical therapy delivered through device for termination of VF episodes

Time frame: 3 years

Secondary Outcomes

Inappropriate ICD Therapy

Caused by lead sensing or programming errors

Time frame: 3 years

Normalization of Brugada ECG pattern

ECG pattern is normal sinus rhythm after catheter ablation

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.